LYSINE SUCCINATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H14N2O2.C4H6O4
Molecular Weight	264.2756
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.NCCCC[C@H](N)C(O)=O

InChI

InChIKey=BOFNEFKSMURYOG-JEDNCBNOSA-N

InChI=1S/C6H14N2O2.C4H6O4/c7-4-2-1-3-5(8)6(9)10;5-3(6)1-2-4(7)8/h5H,1-4,7-8H2,(H,9,10);1-2H2,(H,5,6)(H,7,8)/t5-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C6H14N2O2
Molecular Weight	146.1876
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373

Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 4 (5-HT4) receptor 38 Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616	Antagonist 2849
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine has been studied for the prevention and treatment of herpes infections and cold sores.
Angina pectoris 110 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine supplements may relieve effort-related angina pectoris.
Osteoporosis 101 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine increases the intestinal absorption and reduces the renal elimination of calcium.
Anxiety 275 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist
Heroin dependence 10 Sources: https://www.drugs.com/npp/lysine.html	Palliative	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine acetylsalicylate has been used to detoxify the body after heroin use.
Patent ductus arteriosus 8 Sources: https://www.drugs.com/pro/neoprofen.html	Primary	Approved 8583	NEOPROFEN Approved Use NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date 2006

PubMed

Title	Date	PubMed
Detection of rare malignant cells and their apoptotic fragments in cerebrospinal fluid.	2000 Oct 7	11072949
The antioxidant system beta-D(+) glucose-glucose oxidase-catalase: tests for pyrogenicity and antigenicity.	2001	11247273
Protein profiling comes of age.	2001	11182890
A systematic approach to the analysis of protein phosphorylation.	2001 Apr	11283598
Formation of 1,1'-iminodicarboxylic acid derivatives, 2,6-diketo-piperazine and dibenzodiazocine-2,6-dione by variations of multicomponent reactions.	2001 Apr	11233828
Effect of the degree of fatty acid unsaturation of rat heart mitochondria on their rates of H2O2 production and lipid and protein oxidative damage.	2001 Apr 15	11240164
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli.	2001 Apr 17	11294652
L-lysine reduces nonenzymatic glycation of glomerular basement membrane collagen and albuminuria in diabetic rats.	2001 Feb	11244310
Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease.	2001 Feb	11236841
Hydrolysed protein accelerates the gastrointestinal transport of formula in preterm infants.	2001 Feb	11236051
How does endotoxin trigger inflammation in otitis media with effusion?	2001 Feb	11210878
Combination of HPLC and solid-phase binding assay for isolation and purification of MHC class I and associated peptides using a bladder tumour cell line.	2001 Feb	11180296
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate.	2001 Feb	11168723
Purification and structure elucidation of the N-acetylbacillosamine-containing polysaccharide from Bacillus licheniformis ATCC 9945.	2001 Feb	11168428
Affinity purification of Csk protein tyrosine kinase based on its catalytic requirement for divalent metal cations.	2001 Feb	11162381
Characterization of the lipopolysaccharide of Yersinia pestis.	2001 Feb	11162185
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.	2001 Feb	11156641
Improved sensitivity and specificity of enzyme immunoassays with P1-adhesin enriched antigen to detect acute Mycoplasma pneumoniae infection.	2001 Feb 1	11166097
Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin.	2001 Feb 16	11178953
Identification of a candidate integrin-fraction associated with the activated form of the PDGF-receptor.	2001 Feb 23	11181089
Purification and biophysical characterization of a minimal functional domain and of an N-terminal Zn2+-binding fragment from the human papillomavirus type 16 E6 protein.	2001 Feb 6	11170444
Uptake and accumulation of exogenous docosahexaenoic acid by Chlorella.	2001 Jan	11272831
Influence of lysates of the salivary glands of Lutzomyia longipalpis on the development of a Leishmania-major-like parasite in the skin of the golden hamster.	2001 Jan	11235554
ESR detection of intraphagosomal superoxide in polymorphonuclear leukocytes using 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide.	2001 Jan	11234998
A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins.	2001 Jan	11214173
Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods.	2001 Jan	11207017
Inhibition of the nitrosothiol production of cultured osteoarthritic chondrocytes by rhein, cortisol and diclofenac.	2001 Jan	11178941
IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA).	2001 Jan	11168012
Interaction of poly(rC)-binding protein 2 with the 5'-terminal stem loop of the hepatitis C-virus genome.	2001 Jan	11163645
Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.	2001 Jan	11115616
Continuous cell introduction for the analysis of individual cells by capillary electrophoresis.	2001 Jan 1	11195493
Mechanism of release of urinary Tamm-Horsfall glycoprotein from the kidney GPI-anchored counterpart.	2001 Jan 12	11162486
RNA interference is mediated by 21- and 22-nucleotide RNAs.	2001 Jan 15	11157775
A single-chain variable region immunoglobulin library from the abomasal lymph node of sheep infected with the gastrointestinal nematode parasite Haemonchus contortus.	2001 Jan 26	11182152
Panaxagin, a new protein from Chinese ginseng possesses anti-fungal, anti-viral, translation-inhibiting and ribonuclease activities.	2001 Jan 5	11205866
Purification of recombinant green fluorescent protein using chromatofocusing with a pH gradient composed of multiple stepwise fronts.	2001 Jan-Feb	11170493
Chemical and biological evaluation of endotoxin contamination on natural rubber latex products.	2001 Jun 5	11255197
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.	2001 Mar	11235953
Post-transcriptional effects of extracellular pH on tumour necrosis factor-alpha production in RAW 246.7 and J774 A.1 cells.	2001 Mar	11222111
Investigating the surface expression of the renal type IIa Na+/Pi-cotransporter in Xenopus laevis oocytes.	2001 Mar 1	11284206
Inositol phosphates from barley low-phytate grain mutants analysed by metal-dye detection HPLC and NMR.	2001 Mar 1	11171128
Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.	2001 Mar 15	11275975
Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytanoyl-CoA alpha-hydroxylase-associated protein 1, a novel BAI1-binding protein.	2001 Mar 5	11245925
Western blotting as a method for studying cell-biomaterial interactions: the role of protein collection.	2001 Mar 5	11189044
Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site.	2001 May 11	11278580
Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus.	2001 May 4	11278753

Patents

Sample Use Guides

In Vivo Use Guide

Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.

Route of Administration: Oral

In Vitro Use Guide

In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 11:13:03 GMT 2025` Edited by `admin` on `Wed Apr 02 11:13:03 GMT 2025`
Record UNII	S86UR4ZXF6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LYSINE SUCCINATE

Common Name

English

BUTANEDIOIC ACID, COMPD. WITH L-LYSINE (1:1)

Preferred Name

English

LYSINE, SUCCINATE (1:1), L-

Common Name

English

L-LYSINE, BUTANEDIOATE (1:1)

Common Name

English

SUCCINIC ACID, COMPD. WITH L-LYSINE (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

22857104